A phase 1, randomized, double-blind, dose-escalation cohort study to evaluate the safety, tolerability and pharmacokinetics of a single intravenous infusion of MGAWN1, a neutralizing, humanized, monoclonal antibody (IgG [immunoglobulin] 1K) to West Nile virus, in healthy adults

Trial Profile

A phase 1, randomized, double-blind, dose-escalation cohort study to evaluate the safety, tolerability and pharmacokinetics of a single intravenous infusion of MGAWN1, a neutralizing, humanized, monoclonal antibody (IgG [immunoglobulin] 1K) to West Nile virus, in healthy adults

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2010

At a glance

  • Drugs MGAWN1 (Primary)
  • Indications West Nile virus infections
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms CP-MGAWN1-01
  • Sponsors MacroGenics
  • Most Recent Events

    • 29 Mar 2010 Results published in Antimicrobial Agents and Chemotherapy.
    • 13 Jul 2009 Status changed from active, no longer recruiting to completed according to Macrogenics media release.
    • 25 Oct 2008 Results presented at ICAAC-IDSA 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top